Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

PC563 Anti-hTERT (348-358) Rabbit pAb

This Anti-hTERT (348-358) Rabbit pAb is validated for use in Paraffin Sections, Immunoblotting, Immunofluorescence for the detection of hTERT (348-358).

Anti-hTERT (348-358) Rabbit pAb MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
PC563
  
Purchase on Sigma-Aldrich

Áttekintés

Replacement Information

Kulcsspecifikációk táblázata

Host
Rb
Description
OverviewRecognizes the ~128 kDa hTERT protein in human breast carcinoma.

This product has been discontinued.
Catalogue NumberPC563
Brand Family Calbiochem®
Application Data
Detection of hTERT by staining paraffin sections. Sample: Human breast carcinoma. Primary antibody: Anti-hTERT (348-358) Rabbit pAb (Cat. No. PC563) (2.5 μg/ml). Detection: DAB with methyl green counterstain.
References
ReferencesDe Kok, J.B., et al. 2000. Int. J. Cancer 87, 217.
Kelland, L.R. 2000. Anticancer Drugs 11, 503.
Nowak, J.A. 2000. Clin. Lab. Med. 20, 369.
Kang, S.S., et al. 1999. J. Biol. Chem. 274, 13085.
Nagao, K., et al. 1999. J. Gastroenterol. 34, 83.
Park, T.W., et al. 1999. Int. J. Cancer 84, 426.
Saji, M., et al. 1999. Clin. Cancer Res. 5, 1483.
Yi, X., et al. 1999. Mol. Cell. Biol. 19, 1989.
Counter, C.M., et al. 1998. Oncogene 16, 1217.
Meyerson, M. 1998. Toxicol. Lett. 41, 102.
Ulanar, G.A., et al. 1998. Cancer Res. 58, 4168.
Product Information
FormLiquid
FormulationIn 50 mM sodium phosphate buffer, 50% glycerol, pH 7.5.
Positive controlHuman breast carcinoma tissue
PreservativeNone
Applications
Key Applications Not Western Blot
Not Immunofluorescence
Paraffin Sections
Application NotesParaffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
Immunoblotting (not recommended)
Immunofluorescence (not recommended)
Application CommentsAntibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena synthetic peptide corresponding to amino acids 348-358 of human hTERT
ImmunogenHuman
HostRabbit
IsotypeIgG
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage -20°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalógusszám GTIN
PC563 0

Documentation

Anti-hTERT (348-358) Rabbit pAb MSDS

Title

Safety Data Sheet (SDS) 

Anti-hTERT (348-358) Rabbit pAb Certificates of Analysis

TitleLot Number
PC563

References

Hivatkozások áttekintése
De Kok, J.B., et al. 2000. Int. J. Cancer 87, 217.
Kelland, L.R. 2000. Anticancer Drugs 11, 503.
Nowak, J.A. 2000. Clin. Lab. Med. 20, 369.
Kang, S.S., et al. 1999. J. Biol. Chem. 274, 13085.
Nagao, K., et al. 1999. J. Gastroenterol. 34, 83.
Park, T.W., et al. 1999. Int. J. Cancer 84, 426.
Saji, M., et al. 1999. Clin. Cancer Res. 5, 1483.
Yi, X., et al. 1999. Mol. Cell. Biol. 19, 1989.
Counter, C.M., et al. 1998. Oncogene 16, 1217.
Meyerson, M. 1998. Toxicol. Lett. 41, 102.
Ulanar, G.A., et al. 1998. Cancer Res. 58, 4168.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision07-August-2007 JSW
ApplicationParaffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
Immunoblotting (not recommended)
Immunofluorescence (not recommended)
Application Data
Detection of hTERT by staining paraffin sections. Sample: Human breast carcinoma. Primary antibody: Anti-hTERT (348-358) Rabbit pAb (Cat. No. PC563) (2.5 μg/ml). Detection: DAB with methyl green counterstain.
DescriptionPurified rabbit polyclonal antibody. Recognizes the ~128 kDa hTERT protein.
BackgroundHuman telomerase is composed of three major components–an RNA component (hTERC), and two protein components, telomerase-associated protein (TEP-1) and telomerase reverse transcriptase (hTERT). The hTERT subunit (approximately 128 kDa) is also the catalytic subunit of telomerase. Selective activation of the hTERT subunit has been demonstrated in the majority of tumors relative to its expression in uninvolved somatic cells making it an attractive target for rational drug design. Expression of the hTERT gene product has been documented in a variety of cancers including urothelial cell carcinoma, ovarian tumors, thyroid neoplasia, and hepatocellular carcinoma to name a few. Levels of hTERT RNA and hTERT protein are regulated by a number of mechanisms including both transcriptional and post-translational mechanisms as well as by the activity of other proteins such as the AKT protein.
HostRabbit
Immunogen speciesHuman
Immunogena synthetic peptide corresponding to amino acids 348-358 of human hTERT
IsotypeIgG
Specieshuman, not mouse
Positive controlHuman breast carcinoma tissue
FormLiquid
FormulationIn 50 mM sodium phosphate buffer, 50% glycerol, pH 7.5.
Concentration Label Please refer to vial label for lot-specific concentration
PreservativeNone
CommentsAntibody should be titrated for optimal results in individual systems.
Storage Avoid freeze/thaw
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Toxicity Standard Handling
ReferencesDe Kok, J.B., et al. 2000. Int. J. Cancer 87, 217.
Kelland, L.R. 2000. Anticancer Drugs 11, 503.
Nowak, J.A. 2000. Clin. Lab. Med. 20, 369.
Kang, S.S., et al. 1999. J. Biol. Chem. 274, 13085.
Nagao, K., et al. 1999. J. Gastroenterol. 34, 83.
Park, T.W., et al. 1999. Int. J. Cancer 84, 426.
Saji, M., et al. 1999. Clin. Cancer Res. 5, 1483.
Yi, X., et al. 1999. Mol. Cell. Biol. 19, 1989.
Counter, C.M., et al. 1998. Oncogene 16, 1217.
Meyerson, M. 1998. Toxicol. Lett. 41, 102.
Ulanar, G.A., et al. 1998. Cancer Res. 58, 4168.